EU’s Health Emergency Response Plans Must Address Existing Flaws
New HERA Authority Welcomed By Industry, But Current Weaknesses Highlighted
The EU’s creation of a Health Emergency Response Authority to deal with future health threats has been welcomed by off-patent industry association Medicines for Europe. However, the organization pointed out current policy and regulatory weaknesses that must be addressed if HERA is to be successful.
You may also be interested in...
The EU vaunts its vaccine donations and starts building resilience against future health threats, and the UK MHRA says Moderna can be used as a booster dose. Aviptadil has received scientific advice from the MHRA for its potential use as a treatment for COVID-19 patients.
A “structured dialog” led by the European Commission with pharmaceutical industry stakeholders provides a critical opportunity to address weaknesses in the stability and security of the supply chain by improving the environment for local manufacturing, Medicines for Europe believes.
Medicines for Europe has renewed its call for a modern digital regulatory infrastructure in the wake of the COVID-19 pandemic to bolster communication and preparedness for future health crises, insisting that there is “no further excuse to delay.”